Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH

导出原文传递

翻译打印收藏纠错

作者： Gall, Henning ^[1] ; Vachiery, Jean-Luc ^[2] ; Tanabe, Nobuhiro ^[3] ; Halank, Michael ^[4] ; Orozco-Levi, Mauricio ^[5] ; Mielniczuk, Lisa ^[6] ; Chang, MiKyung ^[7] ; Vogtlaener, Kai ^[8] ; Grueig, Ekkehard ^[9]

作者单位： Fdn Cardiovasc Colombia, Hosp Int Colombia, Santander, Colombia ^[1] Univ Hosp Carl Gustav Carus, Med Clin Pneumol 1, Dresden, Germany ^[2] Justus Liebig Univ Giessen, Dept Internal Med, UGMLC, Klin Str 32, D-35392 Giessen, Germany ^[3] Bayer AG, Berlin, Germany ^[4] Bayer AG, Wuppertal, Germany ^[5] Chiba Univ, Grad Sch Med, Dept Respirol, Chiba, Japan ^[6] Clin Univ Bruxelles, Dept Cardiol, Hop Erasme, Brussels, Belgium ^[7] Univ Ottawa, Heart Inst, Ottawa, ON, Canada ^[8] Univ Hosp, Thorax Clin, Ctr Pulm Hypertens, Heidelberg, Germany ^[9]

关键词 Chronic thromboembolic pulmonary hypertension Endothelin receptor antagonists Phosphodiesterase type 5 inhibitors Pulmonary arterial hypertension Real-world evidence Riociguat

发布时间 2019-02-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交